Matches in DBpedia 2015-10 for { <http://dbpedia.org/resource/BI_224436> ?p ?o }
Showing triples 1 to 65 of
65
with 100 triples per page.
- BI_224436 abstract "BI 224436 is an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site. In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program.".
- BI_224436 atcPrefix "none".
- BI_224436 iupacName "(2S)-[4-(3,4-Dihydro-2H-chromen-6-yl)-3-quinolinyl][(2-methyl-2-propanyl)oxy]acetic acid".
- BI_224436 thumbnail BI_224436.svg?width=300.
- BI_224436 wikiPageID "33394088".
- BI_224436 wikiPageLength "3447".
- BI_224436 wikiPageOutDegree "13".
- BI_224436 wikiPageRevisionID "636765909".
- BI_224436 wikiPageWikiLink Active_site.
- BI_224436 wikiPageWikiLink Allosteric_regulation.
- BI_224436 wikiPageWikiLink Boehringer_Ingelheim.
- BI_224436 wikiPageWikiLink Category:Integrase_inhibitors.
- BI_224436 wikiPageWikiLink Conserved_sequence.
- BI_224436 wikiPageWikiLink Elvitegravir.
- BI_224436 wikiPageWikiLink Enzyme.
- BI_224436 wikiPageWikiLink Gilead_Sciences.
- BI_224436 wikiPageWikiLink HIV.
- BI_224436 wikiPageWikiLink Integrase.
- BI_224436 wikiPageWikiLink Integrase_inhibitor.
- BI_224436 wikiPageWikiLink Investigational_New_Drug.
- BI_224436 wikiPageWikiLink Investigational_new_drug.
- BI_224436 wikiPageWikiLink Raltegravir.
- BI_224436 wikiPageWikiLinkText "BI 224436".
- BI_224436 atcPrefix "none".
- BI_224436 c "24".
- BI_224436 chemspiderid "27289461".
- BI_224436 eliminationHalfLife "25200.0".
- BI_224436 h "25".
- BI_224436 hasPhotoCollection BI_224436.
- BI_224436 inchi "1".
- BI_224436 inchikey "DMWVBLFYARRIDL-QFIPXVFZBP".
- BI_224436 iupacName "-[4--3-quinolinyl][oxy]acetic acid".
- BI_224436 legalStatus "Investigational".
- BI_224436 molecularWeight "391.46".
- BI_224436 n "1".
- BI_224436 o "4".
- BI_224436 smiles "CCO[C@@H]CO".
- BI_224436 stdinchi "1".
- BI_224436 stdinchikey "DMWVBLFYARRIDL-QFIPXVFZSA-N".
- BI_224436 wikiPageUsesTemplate Template:Antiinfective-drug-stub.
- BI_224436 wikiPageUsesTemplate Template:Antiretroviral_drug.
- BI_224436 wikiPageUsesTemplate Template:Drugbox.
- BI_224436 wikiPageUsesTemplate Template:Reflist.
- BI_224436 subject Category:Integrase_inhibitors.
- BI_224436 hypernym Drug.
- BI_224436 type Article.
- BI_224436 type ChemicalSubstance.
- BI_224436 type Drug.
- BI_224436 type Article.
- BI_224436 type Chemical.
- BI_224436 type Drug.
- BI_224436 type Inhibitor.
- BI_224436 type ChemicalObject.
- BI_224436 type Thing.
- BI_224436 type Q8386.
- BI_224436 comment "BI 224436 is an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site.".
- BI_224436 label "BI 224436".
- BI_224436 sameAs m.0h95243.
- BI_224436 sameAs BI_224436.
- BI_224436 sameAs BI_224436.
- BI_224436 sameAs Q4835750.
- BI_224436 sameAs Q4835750.
- BI_224436 wasDerivedFrom BI_224436?oldid=636765909.
- BI_224436 depiction BI_224436.svg.
- BI_224436 isPrimaryTopicOf BI_224436.